Shots:
- AbbVie & Neomorph have partnered in a collaboration & option-to-license deal to develop molecular glue degraders for oncology & immunology, using Neomorph’s molecular glue discovery
- As per the terms, Neomorph will receive upfront & is eligible for ~$1.64B in future option fee & milestones, plus net sales-based royalties
- Molecular glue degraders are small molecules that selectively target & trigger the degradation of proteins responsible for cancer growth or immune system dysregulation
Ref: Prnewswire | Image: AbbVie & Neomorph
Related News:- AbbVie and Simcere Zaiming Collaborate to Develop SIM0500 for Treating Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
